|
|
|
|
238 * !
|
Wed, 8/11/2021,
10:00 AM -
11:50 AM
|
Virtual
|
|
Addressing Nonproportional Hazards Issues in Oncology Clinical Trial Design — Topic-Contributed Papers
|
|
Biopharmaceutical Section, Biometrics Section, Statistics and Pharmacometrics Interest Group
|
|
Organizer(s): Revathi Ananthakrishnan, Bristol-Myers Squibb; Daniel Li, Bristol-Myers Squibb
|
|
Chair(s): Daniel Li, Bristol-Myers Squibb
|
|
10:05 AM
|
New alternative measures to hazard ratio
HAJIME UNO, Dana-Farber Cancer Institute
|
|
10:25 AM
|
Max-Combo Test for Time-to-Event Endpoints Under Nonproportional Hazards
Ray Lin, Genentech
|
|
10:45 AM
|
Design for Immuno-Oncology Clinical Trials with Nonproportional Hazards Patterns
ZHENZHEN XU, FDA; Bin Zhu, National Cancer Institute; YONGSOEK PARK, University of Pittsburg
|
|
11:05 AM
|
A 5-Step Stratified Testing and Amalgamation Routine
Rachel Marceau West, Merck & Co. ; Devan V Mehrotra, Merck & Co., Inc.
|
|
11:25 AM
|
Discussant: Kay Tatsuoka, Bristol Myers Squibb
|
|
11:45 AM
|
Floor Discussion
|
